Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07559760 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

Name: New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer — clinical trial record (NCT07559760)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorThe First Hospital of Jilin University

Started2025-11-01

View on ClinicalTrials.gov ↗

The First Hospital of Jilin University

86 trials monitored

See 2 trials at risk

Colorectal Cancer

2,904 trials monitored

See 127 trials at risk

This is a single-center, single-arm study designed to evaluate the efficacy and safety of second-line treatment in patients with advanced colorectal cancer (those who have progressed on or are intolerant to first-line oxaliplatin-based regimens with or without targeted therapy) receiving Levofolinic Acid + 5-FU continuous infusion combined with irinotecan hydrochloride liposome ± cetuximab/bevacizumab. Approximately 30 patients will be enrolled.

Trial Details

NCT Number	NCT07559760
Lead Sponsor	The First Hospital of Jilin University
Conditions	Metastatic Colorectal Cancer
Enrollment	30 participants
Start Date	2025-11-01
Primary Completion	2027-05-31 (estimated)
Study Completion	2029-05-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-30